entertainment -WSS

entertainment

author：focus 2025-09-06 02:03:32 - browse：39

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： 340B reform proposal comes out of Senate working group

WSS

The Biogen Aduhelm mess could happen again

Cigna wins case to block Amy Bricker's move to CVS

Health care court cases: Humana, Sutter, Novant

Readers discuss the intersection of pregnancy and addiction

Cigna wins case to block Amy Bricker's move to CVS

A single Democrat is willing to weaken Medicare negotiation power

entertainment

entertainment

leisure time

23andMe had bad news about my health. I wish a person had delivered it

California wildfire smoke linked to 52,000 early deaths, study says

Apple is now the first public company to be valued at $3 trillion

Readers discuss the intersection of pregnancy and addiction

Hollywood unions extend contract negotiations for actors

Cano Health’s bankruptcy is a warning for Medicare Advantage

Trump demands the U.S. pay no more for drugs than other countries … again

Why Novartis is going to walk from its acquisition of MorphoSys

Hepatitis C has a cure — but many Americans still lack access to it

The system is set up to fail children with medical complexity

focus

AstraZeneca stays mum on Medicare drug pricing negotiations

Padmanee Sharma of MD Anderson at center of lawsuit over credit

AstraZeneca stays mum on Medicare drug pricing negotiations

STAT Virtual Event: ASCO Recap, Live!

Devoted Health’s losses in Medicare Advantage persist

Cigna wins case to block Amy Bricker's move to CVS

hotspot

hotspot

entertainment

Wikipedia